Prescribing in DID and complex trauma

← Back to therapist resources

There is no medication with a licensed indication for DID. The pharmacological evidence base for dissociative disorders specifically is sparse relative to adjacent conditions — most of what guides clinical practice is extrapolated from C-PTSD, borderline personality disorder, and treatment-resistant depression literature, combined with case series and expert consensus (principally ISSTD Guidelines, 2011, with updates in 2020).

What this means in practice is that most clients with DID arrive in your consulting room already on medications — often prescribed before an accurate dissociative diagnosis was established, targeting comorbidities rather than the core presentation. Your clinical role is rarely to initiate prescribing conversations but frequently to help clients think about what they are taking, why, and whether it is supporting or complicating the therapeutic work.

Evidence overview by drug class

Drug class	Target symptoms	Evidence quality	DID-specific considerations
SSRIs / SNRIs	Depression, anxiety, hyperarousal	Moderate	Reasonable first-line for comorbid depression/anxiety. No direct effect on dissociation. Early activation risk worth monitoring in fragmented systems.
Lamotrigine	Emotional dysregulation, impulsivity	Moderate	Most evidence among mood stabilisers for complex trauma. Slow titration required. Monitor for Stevens-Johnson syndrome (rare). Can support Phase 1 stabilisation work.
Low-dose antipsychotics	Sleep, intrusive symptoms, internal voices	Limited	Risk of suppressing internal communication if voices are dissociative parts rather than psychotic phenomena. May impede therapeutic access to system. Use with caution and close monitoring.
Prazosin	Trauma nightmares	Good (nightmares)	Underused relative to evidence. Well-tolerated. No significant dissociation-specific concerns.
Benzodiazepines	Acute crisis, severe anxiety	Caution	Short-term crisis use only. Risk of tolerance, dependence, and deepening amnesia. Can increase switching frequency in some presentations. Needs crisis-plan framing, not standing prescription.
Ketamine / esketamine	Treatment-resistant depression	Emerging	Strong evidence for TRD. Dissociative side effects require careful monitoring. Not first-line in DID but worth considering when severe depression is blocking therapeutic engagement.
MDMA-assisted therapy	PTSD, trauma processing	Emerging (Phase 3)	Phase 3 PTSD data compelling. DID-specific evidence early. Amygdala downregulation mechanism theoretically advantageous for dissociative presentations; internal fragmentation risks require careful exclusion criteria.
Psilocybin-assisted therapy	Depression, PTSD	Early trials	High destabilisation risk in fragmented presentations. Some researchers consider DID a contraindication for current protocols. Monitor literature but not a routine clinical option in this population yet.

Antidepressants and the dissociative system

SSRIs and SNRIs are the medications most commonly prescribed before a dissociative disorder is identified, and the most commonly continued after diagnosis. They are not inappropriate — comorbid depression occurs in 80-90% of DID presentations (Ross et al., 2002), and a functioning antidepressant reduces the overall symptom burden enough to support therapeutic engagement. The evidence for SSRIs in PTSD (Friedman et al., 2015) is solid enough to extend to complex trauma presentations.

The dissociation-specific concern is early activation: SSRIs can increase emotional intensity in the first 2-6 weeks before stabilising, which in a fragmented system can precipitate switching or flood previously contained trauma material before the therapeutic alliance is robust enough to hold it. This is worth flagging to both client and prescriber if a new SSRI is being initiated during active Phase 1 work.

There is no evidence that SSRIs reduce dissociation itself. Some studies have shown mild reduction in depersonalisation and derealisation as secondary effects, but this is inconsistent. Do not expect SSRIs to address the dissociative structure.

Mood stabilisers and emotional dysregulation

Emotional dysregulation — rapid, intense affective shifts disproportionate to context — is a core feature of complex trauma presentations and a significant barrier to Phase 1 stabilisation. The theoretical basis for mood stabilisers in this population is sound, and lamotrigine has the strongest profile among the options.

Lamotrigine's action on glutamate and sodium channels produces a gradual dampening of affective reactivity without the cognitive side effects of older mood stabilisers or the weight and metabolic risks of sodium valproate. The titration schedule is slow (typically 25mg increments over 6-8 weeks to a therapeutic dose of 100-200mg) — set client expectations accordingly. The main serious risk is Stevens-Johnson syndrome, which is rare but requires client education to recognise early signs (rash, particularly mucosal involvement).

Sodium valproate is occasionally used, particularly in presentations with rapid cycling or cyclothymic features. Its teratogenicity makes it an inappropriate choice for anyone who may become pregnant, and this should be part of any prescribing conversation.

Antipsychotics: the internal voices question

This is the area of greatest clinical risk from a coordination standpoint. Internal voices — whether as commentary, instruction, or argument — are reported by the majority of people with DID. They are almost always dissociative in origin: the voices of other parts of the system. They are almost always ego-dystonic in the early stages of treatment. They are frequently misdiagnosed as psychotic phenomena by clinicians without dissociation training.

When antipsychotics are prescribed for a client you are seeing for dissociation, the therapeutic priority is to ensure the prescribing clinician understands what the voices represent. A shared letter or a joint consultation is often worthwhile. Low-dose quetiapine for sleep or severe intrusive symptoms is less problematic than higher doses targeting voices as the primary symptom.

Benzodiazepines and crisis planning

The case for benzodiazepines in DID is narrow but real: acute dissociative crises — severe depersonalisation/derealisation, flooding, acute switching with loss of containment — can occasionally be stabilised by short-acting benzodiazepines when other regulation strategies have failed. The physiological dampening of the stress response creates a window in which the system can return to a more cooperative state.

The case against standing prescriptions is strong. Benzodiazepine tolerance develops within weeks of regular use. Dependence compounds the clinical picture and adds an additional treatment target. Memory consolidation impairment is documented and directly relevant in a presentation where building continuous memory is part of the therapeutic goal. Some clients report that benzodiazepines increase switching frequency, possibly by reducing the physiological signals that other parts use to recognise a threat and stay co-conscious.

Emerging treatments: what the evidence actually shows

Ketamine and esketamine

The evidence for ketamine in treatment-resistant depression (TRD) is now well-established (Murrough et al., 2013; TRANSFORM-2 and -3 trials for esketamine). Response rates of 50-70% in patients who have not responded to multiple adequate antidepressant trials represent a clinically significant advance. Given the prevalence of severe, chronic, treatment-resistant depression in complex trauma presentations, this is directly relevant to your client population.

The dissociation-specific considerations are important. Ketamine produces a dose-dependent dissociative state as part of its mechanism of action — this is not a side effect but a core pharmacological property. For some clients with DID this is experienced as neutral or even familiar; for others it is destabilising, producing intensified switching or flooding. There is no reliable way to predict individual response without a monitored trial.

The practical implication: if a client with DID is being considered for ketamine treatment for TRD, close coordination between the administering psychiatrist and the trauma therapist is essential. The therapist should have a direct communication channel with the prescribing team to provide early warning of any intensification of dissociative symptoms. The client's crisis plan should be updated before treatment begins.

MDMA-assisted therapy

The MAPS Phase 3 trials for PTSD demonstrated response rates significantly exceeding both psychotherapy and pharmacotherapy comparators — approximately 67% of participants no longer met PTSD criteria at follow-up (Mitchell et al., 2021). The mechanism is well-characterised: MDMA produces significant amygdala downregulation (Carhart-Harris et al., 2015) alongside increased oxytocin and prolactin, producing a state of reduced threat response and increased prosocial connection. This window — typically lasting 6-8 hours — allows traumatic material to be approached with a qualitatively different relationship to fear.

The theoretical case for MDMA-assisted therapy in DID is compelling. The primary mechanism — reduced amygdala activation — is precisely what makes trauma processing so difficult in dissociative presentations: the threat-detection system activates before processing can occur, triggering switching or shutdown. A temporary reduction of that response could create a window in which parts can approach traumatic material that would otherwise produce unmanageable activation.

The significant concern for fragmented systems is intensity management. The MDMA state is powerful, emotionally amplifying, and can bring suppressed material forward rapidly. In a highly fragmented system without significant internal cooperation, this could produce overwhelming flooding rather than productive processing. Current MAPS protocols include fragmented dissociation as a careful risk factor rather than a hard contraindication, but they require substantial pre-treatment stabilisation work — the equivalent of a robust Phase 1 — before the MDMA sessions begin.

Psilocybin-assisted therapy

The evidence for psilocybin in treatment-resistant depression (Carhart-Harris et al., 2021; Davis et al., 2021) and end-of-life anxiety is strong. Effect sizes are large and durable, with response rates comparable to MDMA for depression. The mechanism involves 5-HT2A agonism producing a period of increased neural plasticity and reduced default mode network (DMN) activity — the DMN being associated with self-referential rumination and the maintenance of rigid cognitive patterns.

The risk profile for DID is meaningfully higher than for MDMA. Psilocybin produces a more unpredictable, cognitively intense experience with ego dissolution as a core feature of higher doses. Ego dissolution — the temporary loss of the boundary between self and environment — is experientially destabilising even in well-functioning individuals. In a system where identity coherence is already fragmented and where ego boundaries are a central clinical challenge, the risk of a destabilising or retraumatising experience is significant.

Several researchers in this space, including those with specific DID expertise, currently regard the diagnosis as a contraindication for standard psilocybin protocols. Others are more cautiously interested in exploring adapted low-dose protocols. This is a space to monitor closely in the literature rather than one where clinical referral is appropriate at present, except in the context of formal research settings with DID-specific expertise.

The therapist's role in medication conversations

You are not prescribing. But you are often the most informed clinician in the client's network about the specifics of their dissociative presentation, and you are frequently the first person they ask about medication changes, concerns, and new options they have encountered. A few principles are worth naming explicitly.

First, the voices question. If a client is prescribed antipsychotics for internal voices, advocate clearly with the prescriber — in writing if necessary — that these are understood to be dissociative in origin. This is a clinical responsibility, not scope overreach.

Second, new prescriptions during active trauma work. Any new medication that alters the affective or dissociative state should be flagged in session as a variable that needs tracking. Build in explicit check-ins: what is the client noticing? Are there parts responding differently? Is switching more or less frequent? This information is relevant to the prescriber and you are often better positioned to elicit it.

Third, emerging treatments. Clients are researching MDMA and psilocybin. They will ask. Having an informed, honest answer — including what the evidence says about DID specifically and what the current accessibility picture is — is part of being a well-informed specialist.

Finally, psychiatrist relationships. The most useful thing you can do for a client with complex medication needs is build a direct communication channel with their prescribing psychiatrist. In many NHS contexts this requires advocacy. It is worth the effort. The prescriber knowing that the "internal voices" are parts changes the prescribing decisions; they cannot know this without you telling them.

Client version

Medication and DID: what actually helps

The plain-language version of this review — suitable to share with or recommend to clients.